Azithromycin SR + Amoxiclav 1000 mg
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Maxillary Sinusitis
Conditions
Maxillary Sinusitis
Trial Timeline
Apr 1, 2010 → Mar 1, 2011
NCT ID
NCT01032174About Azithromycin SR + Amoxiclav 1000 mg
Azithromycin SR + Amoxiclav 1000 mg is a pre-clinical stage product being developed by Pfizer for Maxillary Sinusitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01032174. Target conditions include Maxillary Sinusitis.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01032174 | Pre-clinical | Completed |
Competing Products
5 competing products in Maxillary Sinusitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| levofloxacin | Johnson & Johnson | Phase 3 | 77 |
| azithromycin SR (Zithromax; compound: CP-62,993) + levofloxacin | Pfizer | Phase 3 | 76 |
| Telithromycin | Sanofi | Phase 3 | 76 |
| Azithromycin + Telithromycin | Sanofi | Approved | 84 |
| Avelox (Moxifloxacin, BAY12-8039) | Bayer | Approved | 82 |